Table of Contents

- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Preface to sixth edition

- **Chapter 1. What is pharmacology?**
- 1.1. About this book
- 1.2. What is pharmacology?
- 1.3. The receptor concept
- 1.4. Pharmacological test systems
- 1.5. The nature of drug receptors
- 1.6. From the snapshot to the movie
- 1.7. Pharmacological intervention and the therapeutic landscape
- 1.8. System-independent drug parameters: affinity and efficacy
- 1.9. What is affinity?
- 1.10. The Langmuir adsorption isotherm
- 1.11. What is efficacy?
- 1.12. Dose–response curves
- 1.13. Chapter summary and conclusions
- 1.14. Derivations: conformational selection as a mechanism of efficacy

- **Chapter 2. How different tissues process drug response**
- 2.1. The ‘eyes to see’: pharmacologic assays
- 2.2. The biochemical nature of stimulus–response cascades
- 2.3. The mathematical approximation of stimulus–response mechanisms
- 2.4. Influence of stimulus–response cascades on dose–response curve slopes
- 2.5. System effects on agonist response: full and partial agonists
- 2.6. Differential cellular response to receptor stimulus
- 2.7. Receptor desensitization and tachyphylaxis
- 2.8. The measurement of drug activity
- 2.9. Advantages and disadvantages of different assay formats
- 2.10. Drug concentration as an independent variable
- 2.11. Chapter summary and conclusions
- 2.12. Derivations

- **Chapter 3. Drug–receptor theory**
- 3.1. About this chapter
- 3.2. Drug–receptor theory

- 3.3. The use of mathematical models in pharmacology
- 3.4. Some specific uses of models in pharmacology
- 3.5. Mass action building blocks
- 3.6. Classical model of receptor function
- 3.7. The operational model of receptor function
- 3.8. Two-state theory
- 3.9. The ternary complex model
- 3.10. The extended ternary complex model
- 3.11. Constitutive receptor activity and inverse agonism
- 3.12. The cubic ternary complex model
- 3.13. Multistate receptor models and probabilistic theory
- 3.14. Chapter summary and conclusions
- 3.15. Derivations

- **Chapter 4. Pharmacological assay formats: binding**
- 4.1. The structure of this chapter
- 4.2. Binding theory and experiment
- 4.3. Complex binding phenomena: agonist affinity from binding curves
- 4.4. Experimental prerequisites for correct application of binding techniques
- 4.5. Binding in allosteric systems
- 4.6. Chapter summary and conclusions
- 4.7. Derivations

- **Chapter 5. Drug targets and drug-target molecules**
- 5.1. Defining biological targets
- 5.2. Specific types of drug targets
- 5.3. Small drug-like molecules
- 5.4. Biologics
- 5.5. Summary and conclusions

- **Chapter 6. Agonists: the measurement of affinity and efficacy in functional assays**
- 6.1. Functional pharmacological experiments
- 6.2. The choice of functional assays
- 6.3. Recombinant functional systems
- 6.4. Functional experiments: dissimulation in time
- 6.5. Experiments in real time versus stop-time
- 6.6. Quantifying agonism: the Black–Leff operational model of agonism
- 6.7. Biased signaling
- 6.8. Null analyses of agonism
- 6.9. Comparing full and partial agonist activities: Log(max/EC50)
- 6.10. Chapter summary and conclusions

- 6.11. Derivations

- **Chapter 7. Orthosteric drug antagonism**
- 7.1. Introduction
- 7.2. Kinetics of drug–receptor interaction
- 7.3. Surmountable competitive antagonism
- 7.4. Noncompetitive antagonism
- 7.5. Agonist–antagonist hemiequilibria
- 7.6. Resultant analysis
- 7.7. Antagonism in vivo
- 7.8. Blockade of indirectly acting agonists
- 7.9. Irreversible antagonism
- 7.10. Chemical antagonism
- 7.11. Chapter summary and conclusions
- 7.12. Derivations

- **Chapter 8. Allosteric modulation**
- 8.1. Introduction
- 8.2. The nature of receptor allosterism
- 8.3. Unique effects of allosteric modulators
- 8.4. Functional study of allosteric modulators
- 8.5. Functional allosteric model with constitutive activity
- 8.6. Internal checks for adherence to the allosteric model
- 8.7. Methods for detecting allosterism
- 8.8. Chapter summary and conclusions
- 8.9. Derivations

- **Chapter 9. The optimal design of pharmacological experiments**
- 9.1. Introduction
- 9.2. The optimal design of pharmacological experiments
- 9.3. Null experiments and fitting data to models
- 9.4. Interpretation of experimental data
- 9.5. Predicting therapeutic activity in all systems
- 9.6. Summary and conclusions
- 9.7. Derivations

- **Chapter 10. Pharmacokinetics**
- 10.1. Introduction
- 10.2. Biopharmaceutics
- 10.3. The chemistry of “drug-like” character
- 10.4. Pharmacokinetics
- 10.5. Nonlinear pharmacokinetics
- 10.6. Multiple dosing

- 10.7. Modifying pharmacokinetics through medicinal chemistry
- 10.8. Practical pharmacokinetics
- 10.9. Placement of pharmacokinetic assays in discovery and development
- 10.10. The pharmacokinetics of biologics
- 10.11. Summary and conclusions

- **Chapter 11. Safety pharmacology**
- 11.1. Safety pharmacology
- 11.2. Hepatotoxicity
- 11.3. Cytotoxicity
- 11.4. Mutagenicity
- 11.5. hERG activity and Torsades de Pointes
- 11.6. Autonomic receptor profiling and off-target effects
- 11.7. General pharmacology
- 11.8. Clinical testing and drug toxicity
- 11.9. Summary and conclusions

- **Chapter 12. The drug-discovery process**
- 12.1. Some challenges for modern drug discovery
- 12.2. The drug-discovery process
- 12.3. Target-based drug discovery
- 12.4. Systems-based drug discovery
- 12.5. High-throughput screening
- 12.6. The lead optimization process
- 12.7. Drug effectiveness
- 12.8. Summary and conclusions

- **Chapter 13. Selected pharmacological methods**
- 13.1. Binding experiments
- 13.2. Functional assays
- Appendix 1. Statistics
- Index